ClinicalTrials.gg
TerminatedNCT05802303Updated Mar 28, 2024

Estrogen (Gel)Transdermal vs Oral Estrogen for Endometrial Preparation

An interventional study of 17-beta Estradiol gel 0.06% w/w(ESTOGEL.Intas pharma) and Estradiol Hemihydrate(Estrabet Tablet, abbott pharma) in Frozen Embryo Transfer and Infertility, Female, sponsored by Indira IVF Hospital Pvt Ltd. Terminated at 1 site in India. Open to female participants aged 25 Years to 35 Years. Per ClinicalTrials.gov, last updated 2024-03-28.

Sponsored by Indira IVF Hospital Pvt Ltd · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
As per institutional protocol unable to recruit adequate number of patients

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
25 Years to 35 Years
Sex
Female
01

Study summary

The goal of this randomized study trial is to comparing transdermal estradiol gel and oral estradiol for endometrial preparation in the Frozen Embryo Transfer Cycle. The main question[s] it aims to answer is: • Can Transdermal estrogen (gel) can be equally efficacious as compared to oral estrogen in hormone replacement FET (HRT- FET) cycles ? The Transdermal gel would have the added benefit of a higher patient comfort with fewer side effects and a better safety profile. Participants planned for Frozen embryo transfer will undergo H-P-O axis suppression on previous cycle D21 of menses with gonadotropin-releasing hormone(GnRH) agonist depot preparation (Inj. Decapeptyl 3.75 mg) IM . The study will compare Transdermal E2 gel with Oral E2 tabs. The patients will be randomized into an oral and gel group, and all patients will participate only once in the study.

Read the detailed description

Estrogen priming is essential for the induction of progesterone receptors and to build endometrial thickness, both of which play an important role in regulating endometrial receptivity . Different routes of Estrogen administration are oral (tablets), transdermal (patch/gel), and vaginal (tablets).

02

Conditions studied

  • Frozen Embryo Transfer
  • Infertility, Female

Browse trials for

Keywords

  • Transdermal Estrogen
  • FET
  • Oral Estrogen
  • IVF/ICSI
03

In context

Infertility, Female

553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.

This study's enrollment of 172 is above the median of 100 across 378 interventional studies indexed under Infertility, Female.

Browse Infertility, Female studies →

Lead sponsor

Indira IVF Hospital Pvt Ltd is the lead sponsor of 7 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infertile patients aged 23-35 years.
  • 18.5 to 29.9 kg/m2.
  • A normal uterine cavity assessed by 3D ultrasound (USG)/hysteroscopy.
  • Patients who underwent IVF/ICSI and who have cryopreserved their embryos.
  • Those receiving donor oocytes or donor embryos.
  • Patients undergoing hormonal replacement frozen embryo transfer (HRT-FET) cycles with GnRH agonist suppression.
  • Embryo Transfers of good quality embryos -2/3/4/5 AA, AB, BA(As per Gardner Grading System).

Exclusion criteria

Exclusion Criteria:

  • Preimplantation Genetic Testing for Aneuploidies (PGT-A) cycles.
  • Patients who had a FET performed in natural or stimulated cycles.
  • Patients who had more than 2 failed transfers due to thin endometrium.
  • Patients having uterine anomalies.
  • Known cases of adenomyosis and endometriosis.
  • Underlying cardiac/renal/hepatic/thromboembolic disorders, h/o anxiety or depression.
  • E2 >50 pg./ml, P4 > 1 ng/ml and on D2 of menses.
  • On D2 scan presence of a cyst or a dominant follicle.
  • Patients with a history of recurrent 1st-trimester abortions.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
172 participants (actual)

Study arms

  • Active comparator
    Transdermal Gel

    In the Estradiol gel group patients will be administered transdermal Estradiol gel (17-beta Estradiol gel 0.06%)

    Drug: 17-beta Estradiol gel 0.06% w/w(ESTOGEL.Intas pharma)

  • Other
    Oral Estradiol

    In the Oral Estradiol group, all women will be given oral Estradiol valerate tablets

    Drug: Estradiol Hemihydrate(Estrabet Tablet, abbott pharma)

Interventions

  • Drug17-beta Estradiol gel 0.06% w/w(ESTOGEL.Intas pharma)

    Drug page: EstradiolStudies of EstradiolEstradiol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    In the Estradiol gel group patients will be administered transdermal Estradiol gel (17-beta Estradiol gel 0.06% w/w) 2 puffs thrice a day (each application contains 1.25 mg with 0.75 mg of the drug).

  • DrugEstradiolStudies of EstradiolEstradiol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    In the oral Estradiol group, all women will be given 2 mg of Estradiol valerate tablets, one tablets thrice a day within 30 days of injection triptorelin depot. Endometrial assessment will be performed on D10 of HRT. Please see the flow diagram (in the annexure) for details.

06

What researchers measure

Primary outcomes

  1. Endometrial thickness (ET)

    Average endometrial thickness achieved on day 14 of HRT

    Time frame: 14 to 21 days after start of estrogen

Secondary outcomes

  1. Cycle cancelation rate

    Number of cycles cancelled before embryo transfer × 100

    Time frame: 21 days after starting HRT

  2. Average E2 consumption

    Total E2 consumed till embryo transfer

    Time frame: On 1 day of embryo transfer

  3. Implantation rates (IR)

    The number of gestational sacs observed by transvaginal ultrasound at the 6th gestational week per the number of embryos transferred.

    Time frame: 4 weeks + 2 weeks after embryo transfer

  4. Clinical pregnancy rates (CPR)

    Detection of a foetal heartbeat on transvaginal ultrasound at the 6th gestational week per embryo transfer cycle

    Time frame: 4 weeks + 2 weeks after embryo transfer

  5. Miscarriage rates (MR)

    Number of spontaneous pregnancy losses in which a gestational sac was previously observed (before gestation week \<20 weeks) per 100 clinical pregnancy .

    Time frame: Within 20 weeks of gestation

  6. Patient satisfaction score

    It is measured using visual analogue scale(VAS) score

    Time frame: on 1 day of embryo transfer

Other outcomes

  1. Undesirable side effects between both the groups

    Symptoms like rash, itching ,burning, thromboembolic event

    Time frame: Till 12 weeks of pregnancy

07

Study locations

1 site
  • Indira IVF Hospital Private Limited
    Udaipur, Rajasthan 313001, India
08

References and documents

Publications

  • Bourdon M, Santulli P, Kefelian F, Vienet-Legue L, Maignien C, Pocate-Cheriet K, de Mouzon J, Marcellin L, Chapron C. Prolonged estrogen (E2) treatment prior to frozen-blastocyst transfer decreases the live birth rate. Hum Reprod. 2018 May 1;33(5):905-913. doi: 10.1093/humrep/dey041. PubMed 29529202 ↗
  • Scheffer JB, Scheffer BB, Aguiar APS, Franca JB, Lozano DM, Fanchin R. A comparison of the effects of three different estrogen used for endometrium preparation on the outcome of day 5 frozen embryo transfer cycle. JBRA Assist Reprod. 2021 Feb 2;25(1):104-108. doi: 10.5935/1518-0557.20200059. PubMed 32991118 ↗
  • Corroenne R, El Hachem H, Verhaeghe C, Legendre G, Dreux C, Jeanneteau P, Descamps P, May-Panloup P, Bouet PE. Endometrial preparation for frozen-thawed embryo transfer in an artificial cycle: transdermal versus vaginal estrogen. Sci Rep. 2020 Jan 22;10(1):985. doi: 10.1038/s41598-020-57730-3. PubMed 31969591 ↗
  • Devroey P, Pados G. Preparation of endometrium for egg donation. Hum Reprod Update. 1998 Nov-Dec;4(6):856-61. doi: 10.1093/humupd/4.6.856. PubMed 10098476 ↗
  • Garimella S, Karunakaran S, Gedela DR. A prospective study of oral estrogen versus transdermal estrogen (gel) for hormone replacement frozen embryo transfer cycles. Gynecol Endocrinol. 2021 Jun;37(6):515-518. doi: 10.1080/09513590.2020.1793941. Epub 2020 Jul 15. PubMed 32666854 ↗
  • Ranisavljevic N, Raad J, Anahory T, Grynberg M, Sonigo C. Embryo transfer strategy and therapeutic options in infertile patients with thin endometrium: a systematic review. J Assist Reprod Genet. 2019 Nov;36(11):2217-2231. doi: 10.1007/s10815-019-01576-w. Epub 2019 Sep 9. PubMed 31502111 ↗
  • Paulson RJ. Hormonal induction of endometrial receptivity. Fertil Steril. 2011 Sep;96(3):530-5. doi: 10.1016/j.fertnstert.2011.07.1097. PubMed 21880274 ↗
  • Shahrokh Tehraninejad E, Kabodmehri R, Hosein Rashidi B, Jafarabadi M, Keikha F, Masomi M, Hagholahi F. Trans dermal estrogen (oestrogel) for endometrial preparation in freeze embryo transfer cycle: An RCT. Int J Reprod Biomed. 2018 Jan;16(1):51-56. PubMed 29675488 ↗

Individual participant data

Plan to share: Yes — IPD will be shared with other researchers after publication of primary results

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: After 6 months of publication of primary results

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Mar 2024, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2023
First posted
Apr 6, 2023
StartActual
Jul 25, 2023
Primary completionActual
Mar 26, 2024
CompletionActual
Mar 26, 2024
Last update
Mar 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05802303
Lead sponsor
Indira IVF Hospital Pvt Ltd
Responsible party
Dr Vipin Chandra (Chief Clinical Lab Operations, Indira IVF Hospital Pvt Ltd) — Principal investigator
First posted
Apr 6, 2023
Start date
Jul 25, 2023
Primary completion
Mar 26, 2024
Completion
Mar 26, 2024
Last update
Mar 28, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion